TELES AG Informationstechnologien: TELES sales forecast 2022: More than EUR 55 million expected (2020: EUR 2.8 million)

Berlin (pta029/16.12.2021/14:00 UTC+1)

TELES AG Informationstechnologien (ISIN DE000A289B07 / WKN A289B0) expects sales of 55 to 60 million euros for the 2022 financial year. This significant jump in sales is due to the very good business development in the area Drug supply achieved.

Driven by the two acquisitions GVL Rechenzentrum GmbH (GVL) and EURO RX Arzneimittel GmbH (EURO RX), TELES 'sales will increase by a factor of 20 in 2022 compared to 2020.

With the expansion field Pharma in 2021, TELES has opened up a new segment in which, as in telecommunications software, the management of large amounts of data and the digitization of business processes lead to growth spurts.

GVL Rechenzentrum GmbH is a specialized pharmacy data center that is playing a pioneering role in the implementation of the future electronic prescription. This means that simpler billing variants will be possible in the future between pharmacies and health insurance companies, which can also support health services research for the pharmaceutical industry.

The second acquisition - EURO RX - is a specialized drug supplier that guarantees optimal pharmaceutical care for patients with a digitized supply chain. Due to the high level of automation, the EURO RX can deliver drugs for cancer, autoimmune deficits and combination therapies of personalized medicine quickly and reliably throughout Europe. The demand for indication-specific drugs is increasing across Europe and EURO RX GmbH in particular is well positioned to benefit from this growth.

In the Carrier Solutions segment, the trend towards constant upgrades and extended support for software solutions will continue. In this segment we expect sales of EUR 3 million without taking possible inorganic growth into account.

TELES will continue to work actively on cooperations and acquisitions in the software and service area of ​​the telecommunications market as well as in the expansion field of drug supply and digitization.

Oliver Olbrich

CEO

Important instructions

This publication constitutes neither an offer to sell nor a solicitation to buy securities.

This announcement may not be published, distributed or transmitted in the United States of America, Australia, Japan or Canada. This release does not constitute an offer to purchase securities or a solicitation of an offer to purchase securities of TELES AG Informationstechnologien (the 'Shares') in the United States, Germany or other states. Shares may be registered in the United States only after prior registration or without prior registration only due to derogation from the registration requirement under the U.S. Securities Act of 1933 in the currently valid version (the 'Securities Act') are sold or offered for sale. The shares are not and will not be registered under the Securities Act.

(end)

Emitter:	TELES AG Informationstechnologien Ordensmeisterstraße 15-16 12099 Berlin Germany
Contact Person:	Oliver Olbrich
Phone:	+49 30 399 28 00
E-Mail:	legal@teles.com
Website:	www.teles.com
ISIN(s):	DE000A289B07 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart